The effect of geniposide on chronic unpredictable mild stress‐induced depressive mice through BTK/TLR4/NF‐κB and BDNF/TrkB signaling pathways
Authors:
- 8 November 2020
- journal article
- research article
- Published by Wiley in Phytotherapy Research
- Vol. 35 (2) , 932-945
Abstract
The purpose of this study was to estimate the pharmacological effect of geniposide (GEN) on depression, caused by chronic unpredictable mild stress (CUMS), and explore its potential mechanism. During the 6 week CUMS procedure, the mice were treated with GEN (10, 40 mg/kg) by gavage once daily for 3 weeks. As a result, the GEN treatment remarkably improved the behavioral manifestations and suppressed the generations of inflammatory cytokines both in vivo and in vitro. The MDA level was significantly increased, while the activities of SOD, GSH‐PX were decreased in CUMS‐challenged mice and corticosterone‐stimulated PC12 cells. GEN administration significantly inhibited those changes. Moreover, GEN treatment could downregulate the expressions of p‐BTK, TLR4, MyD88, p‐NF‐κB proteins, and upregulate BDNF, p‐TrkB generations in CUMS‐induced mice. Moreover, GEN administration inhibited the protein levels of p‐BTK, TLR4, MyD88, p‐NF‐κB in corticosterone‐induced PC12 cell. In summary, the results suggested that GEN exerted a therapeutic effect on CUMS‐induced depressive mice possibly through the regulation of BTK/TLR4/NF‐κB and BDNF/TrkB signaling pathways.Keywords
Funding Information
- Fundamental Research Funds for the Central Universities (2632017PY14)
This publication has 37 references indexed in Scilit:
- The Association Between Adverse Childhood Experiences and Inflammation in Patients with Major Depressive Disorder: A Systematic ReviewJournal of Affective Disorders, 2020
- Upregulation of antioxidant thioredoxin by antidepressants fluoxetine and venlafaxinePsychopharmacology, 2019
- Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumoniaMolecular Medicine, 2019
- Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysisThe Lancet, 2018
- Targeting the Endocannabinoid/CB1 Receptor System For Treating Major Depression Through Antidepressant Activities of Curcumin and Dexanabinol-Loaded Solid Lipid NanoparticlesCellular Physiology and Biochemistry, 2017
- Decreased Prostaglandin D2 Levels in Major Depressive Disorder Are Associated with Depression-Like BehaviorsInternational Journal of Neuropsychopharmacology, 2017
- Neurotrophins and Proneurotrophins: Focus on Synaptic Activity and Plasticity in the BrainThe Neuroscientist, 2017
- Hippocampal Neuroinflammation, Functional Connectivity, and Depressive Symptoms in Multiple SclerosisBiological Psychiatry, 2016
- ProBDNF Signaling Regulates Depression-Like Behaviors in Rodents under Chronic StressNeuropsychopharmacology, 2016
- Sigma-1 receptor chaperone and brain-derived neurotrophic factor: Emerging links between cardiovascular disease and depressionProgress in Neurobiology, 2013